Tesamorelin

Also known as: Egrifta, TH9507

Growth HormoneFDA APPROVED

Clinical Status

FDA Approved — HIV lipodystrophy.

Mechanism of Action

Stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. Specifically reduces visceral adipose tissue while having minimal effect on subcutaneous fat.

Dosing Defaults

Dose

2 mg

Frequency

1x daily

Administration

Subcutaneous injection

Timing

Before bed (fasted)

Food

fasted

Duration

Indefinite for approved indication

Dose range: 1.28-2 mg daily

Works best on empty stomach, timed with natural GH release during sleep.

Side Effects

•Injection site reactions
•Joint pain
•Peripheral edema
•Muscle pain
•Increased diabetes risk
•May elevate blood glucose

Contraindications & Warnings

⚠Active malignancy
⚠Pregnancy

•Not medical advice
•FDA approved for HIV lipodystrophy only

Compare

Compare Tesamorelin with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Tesamorelin dose.

Open Calculator

Related Growth Hormone Peptides

Ipamorelin

PHASE 2

Growth Hormone

Selective GH secretagogue. Considered one of the safest GHRPs.

CJC-1295

PHASE 2

Growth Hormone

Synthetic GHRH analog that stimulates GH release from the pituitary.

CJC-1295 DAC

PHASE 2

Growth Hormone

Long-acting version of CJC-1295 with extended half-life via albumin binding.

Sermorelin

FDA APPROVED

Growth Hormone

Truncated GHRH analog. Previously FDA-approved for pediatric GH deficiency.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.